Slide 1: Exchange filing cover letter for investor presentation
Date: May 26, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoi Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Bandra-Kurla Complex, Mumbai - 400001. Bandra (East), Mumbai - 400051. Scrip Code: 524404 Symbol: MARKSANS S
Slide 2: Earnings Presentation Q4 and FY26
Earnings Presentation Q4 and FY26 26th May 2026 BSE: 524404 | NSE: MARKSANS | ISIN: INE750C01026 ©2025 – Marksans Pharma Ltd., All Rights Reserved www.marksanspharma.com
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by Marksans Pharma Limited (the “Company”) solely for informational purposes. The information contained herein is not intended to be comprehensive and should not be relied upon as the sole basis for any investment or business decision. This presentatio
Slide 4: Table of Contents
FY26 Financial and Business Highlights 01 FY26 Financial and Business Highlights 04 Q4FY26 Financial and Business Highlights 02 Q4FY26 Financial and Business Highlights 10 Geographical Highlights 03 Geographical Highlights 14 Table of 04 Marksans Pharma at a Glance Marksans Pharma at a Glance 22 Con
Slide 5: FY26 Financial & Business Highlights
FY26 Financial & Business Highlights www.marksanspharma.com Page 4
Slide 6: Management Commentary
Management Commentary Mark Saldanha “FY26 has been a milestone year for Marksans Pharma, we successfully delivered on our guidance with highest-ever total income at ~₹3,000 crore, EBITDA at ₹601 crore (margin 20.4%) and an all-time high PAT of MANAGING DIRECTOR AND CEO ₹420 crore. Growth was led by
Slide 7: Financial Highlights FY26 – YoY Performance
Financial Highlights FY26 – YoY Performance FY26 FY25 YoY Growth % YoY Performance ₹ 3,033 cr ₹ 2,689 cr 12.8% • Growth is driven by new product launches, market Total Income share gains in the key regions, especially US and Australia and favorable currency movement Gross Profit ₹ 1,674 cr ₹ 1,479 c
Slide 8: Financial & Other Highlights – FY26
Financial & Other Highlights – FY26 Revenue contribution for FY26: US - ₹ 1,533 cr | UK & Europe - ₹ 1,015 cr | Australia & New Zealand - ₹ 303 cr | RoW - ₹ 99 cr Research & development (R&D) spends at ₹ 89 cr in FY26, 3.0% of consolidated revenue Cash generated from operations at ₹ 458 cr during FY
Slide 9: FY26 Revenue by Geography
FY26 Revenue by Geography US & North America - ₹ 1,533 cr UK & Europe - ₹ 1,015 cr 24% YoY 1% YoY 52.0% 34.4% 3.4% 10.3% RoW - ₹ 99 cr 4% YoY Australia & New Zealand - ₹ 303 cr 20% YoY www.marksanspharma.com Page 8
Slide 10: Revenue by Therapeutic Segment – FY26
Segmental Revenue FY26 Revenue by Therapeutic Segment – FY26 Revenue by Segment 1,310.8 Rx, 20.0% 460.9 384.0 183.4 171.5 171.5 161.2 54.8 38.4 9.4 5.0 OTC, 80.0% Anti-Allergic Anti-Daibetic Anti -Infectives Gastrointestinal Cardiovascular System(CVS) Anti-cancer supplements (VMS) Anti-hair fall Pai
Slide 11: Q4FY26 Financial & Business Highlights
Q4FY26 Financial & Business Highlights www.marksanspharma.com Page 10
Slide 12: Financial Highlights Q4FY26 – QoQ Performance
Financial Highlights Q4FY26 – QoQ Performance Q4FY26 Q3FY26 QoQ Growth % QoQ Performance • Driven by new launches in Australia and UK; UK Revenue ₹ 856.1 cr ₹ 754.4 cr 13.5% price erosion has stabilized; first Rx branded products launched in Australia this quarter Gross Profit ₹ 465.5 cr ₹ 438.2 cr
Slide 13: Financial Highlights Q4FY26 – YoY Performance
Financial Highlights Q4FY26 – YoY Performance Q4FY26 Q4FY25 YoY Growth % YoY Performance • Growth led by Australia & NZ (+61% YoY) and US & Revenue ₹ 856.1 cr ₹ 708.5 cr 20.8% North America (+24% YoY), reflecting traction from new product launches and expansion across OTC store brands Gross Profit ₹
Slide 14: Quarterly Financial Trends
Quarterly Financial Trends Operating Revenue (₹ cr) Gross Profit (₹ cr) & Gross Margin (%) 856 465 438 412 754 383 358 709 720 60.0% 620 57.8% 57.2% 58.1% 54.1% 54.4% 40.0% Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 EBITDA (₹ cr) & EBITDA Margin (%) Net Income (₹ cr) & Net
Slide 15: Q4 & FY26 Geographical Highlights
Q4 & FY26 Geographical Highlights www.marksanspharma.com Page 14
Slide 16: US and North America Performance
US and North America Performance Annual Performance (₹ cr) Quarterly Performance (₹ cr) 412 406 1,533 387 1,237 329 328 918 775 635 FY22 FY23 FY24 FY25 FY26 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 FY26 Revenue ₹ 1,533 cr 24.0% YoY Q4FY24 ₹ 406 cr 23.6% YoY 1.5% QoQ Highlights Highlights • US & North Amer
Slide 17: UK & Europe Performance
UK & Europe Performance Annual Performance (₹ cr) Quarterly Performance (₹ cr) 1,030 1,015 943 308 274 258 768 245 609 204 FY22 FY23 FY24 FY25 FY26 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 FY26 Revenue ₹ 1,015 cr 1.4% YoY Q4FY24 ₹ 308 cr 12.3% YoY 19.2% QoQ Highlights Highlights • Second largest market co
Slide 18: Australia & New Zealand Performance
Australia & New Zealand Performance Annual Performance (₹ cr) Quarterly Performance (₹ cr) 303 123 253 209 219 180 76 57 61 61 FY22 FY23 FY24 FY25 FY26 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 FY26 Revenue ₹ 303 cr 19.9% YoY Q4FY24 ₹ 123 cr 61.3% YoY 100.9% QoQ Highlights Highlights • Australia & NZ deliv
Slide 19: Australia & New Zealand Product Launches (Apr 2025 – Mar 2026)
Australia & New Zealand Product Launches April 2025 – March 2026 www.marksanspharma.com Page 18
Slide 20: Australia & New Zealand Product Launches (Apr 2026 – Mar 2027)
Australia & New Zealand Product Launches April 2026 – March 2027 www.marksanspharma.com Page 19
Slide 21: Australia & New Zealand Product Launches
Australia & New Zealand Product Launches Nova Pharma : Launched Branded Prescription Division in FY26 Launched 11 Rx brands in FY26 Product Name Active Strength Pack Size Pack Form Reference Brand betamethasone Aluminium tube fitted with a white HDPE DIPROVANT 0.5 mg/g 15g and 50g DIPROSONE dipropio
Slide 22: RoW Business Performance
RoW Business Performance Annual Performance (₹ cr) Quarterly Performance (₹ cr) 100 104 99 32 97 29 27 67 22 19 FY22 FY23 FY24 FY25 FY26 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 FY26 Revenue ₹ 99 cr 4.1% YoY Q4FY24 ₹ 19 cr 35.7% YoY 15.9% QoQ Highlights Highlights • RoW comprises of emerging markets inclu
Slide 23: Marksans Pharma at a Glance
Marksans Pharma at a Glance www.marksanspharma.com Page 22
Slide 24: Company Overview
Company Overview ₹ 3,033 cr 20.4% ₹ 990cr 4 350+ Total Income FY26 Cash balance 4 Manufacturing Products for FY26 EBITDA Margin (as of 31st Mar 2026) Units & and 2,000+ SKUs 4 R&D Centers ~$175mn Amongst Accreditations 2,000+ in US Top 5 USFDA, UK MHRA, Total Employees Amongst the top Indian Austral
Slide 25: Marksan's OTC Focus
Marksan’s OTC Focus Marksan’s OTC Portfolio Industry Opportunity ❖ According to IQVIA, Global OTC Market size is ❖ The OTC business includes store brands, private projected to be $215 bn in 2026 label manufacturing for retailers and customers ❖ Prescription (Rx) to over-the-counter (OTC) ❖ It also m
Slide 26: Manufacturing Capabilities
Manufacturing Capabilities Manufacturing Facility in Farmingdale, USA Total Capacity : 26 bn units p.a.* • Manufactures hard gels, tablets and capsules • Spread over an area of 7,000 sq. mt. USA • "Made in the USA” product offering • Added incremental packaging lines Manufacturing Facility in Southp
Slide 27: Expanding Global Consumer Healthcare Presence
Expanding Global Consumer Healthcare Presence United States ESTABLISHED United Kingdom ESTABLISHED Australia & New Zealand ESTABLISHED • USD 100mn+ revenue — Top-5 Indian pharma company in • ~USD 175mn revenue — #1 market, ~52% of total revenue • USD 50mn+ revenue — established since 2006 via Nova U
Slide 28: R&D Capabilities
R&D Capabilities R&D (₹ cr) and R&D % to sales 3.0% 89 2.2% R&D Southport, 2.0% Farmingdale, United Kingdom 1.5% 1.6% 1.6% United States Navi Mumbai, 1.4% 58 India Goa, India Centers 0.6% 0.6% 0.7% 35 30 29 19 15 8 5 5 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 Continued focus on R&D Plans to
Slide 29: Marksan's Journey
Marksan’s Journey www.marksanspharma.com Page 28
Slide 30: Our Key Events
Our Key Events • Raised ₹ 372.40 cr in Increased focus on OTC equity via conversion segment in US market OTC Segment’s Spun off into a separate of warrants issued to entity - Glenmark OrbiMed and Revenue crossed ₹ • Acquired Bells, Sons & Promoters 2,000 cr revenue Laboratories Ltd. Co. (Druggists)
Slide 31: Growth and Achievements Since 2017
Growth and Achievements Since 2017 Operating Revenue OTC Revenue Consistent and Consistent Manufacturing meaningfully growth in cash capacity SKUs growth growth of high EBITDA from increased from growth to ~3.8x to ~5.3x to ₹ 2,951 cr ₹ 2,361 cr margin operations over 6 bn units p.a. in ~2000+ expan
Slide 32: Financial Trends – High Growth Trajectory
Financial Trends – High Growth Trajectory Operating Revenue (₹ cr) EBITDA (₹ cr) & EBITDA Margin (%) 3,500.0 2,951 700.0 30.0% 24.7% 20.3% 20.4% 2,623 21.1% 3,000.0 600.0 25.0% 17.4% 2,177 2,500.0 500.0 18.3% 2,000.0 1,852 17.0% 20.0% 1,491 13.2% 400.0 1,376 15.0% 1,500.0 1,134 5.8% 8.6% 601 1,005 3
Slide 33: Financial Trends – High Growth Trajectory
Financial Trends – High Growth Trajectory Total Assets (₹ cr) Net Debt to EBITDA 4,500.0 3,861 2.0x 1.6x 4,000.0 1.0x 1.5x 3,500.0 3,240 0.5x 1.0x 3,000.0 2,681 0.5x 2,500.0 2,190 0.0x 2,000.0 1,640 -0.5x 1,228 -0.4x -0.6x 1,500.0 897 -1.0x 1,000.0 752 732 804 -1.2x -1.3 -1.5x 500.0 -2.0x -1.5x -1.6
Slide 34: Proven Success in Acquisitions
Proven Success in Acquisitions Acquisitions Acquired manufacturing unit in Goa from Teva Pharma United United Target Country Australia United States UAE India Kingdom Kingdom Transaction December 31, March 24, 2006 August 27, 2008 June 30, 2015 April 25, 2022 April 19, 2023 Date 2007 Sales growth fr
Slide 35: Strategic Initiatives
Strategic Initiatives www.marksanspharma.com Page 34
Slide 36: Core Strategies for Future Growth
Core Strategies for Future Growth To become the most reliable partner in the consumer healthcare space Focus on store brand OTC Segment • Expanding within proven OTC demand areas, expanding market share with customers and key regions. Aim to capture a significant part of the multi-billion-dollar OTC
Slide 37: Capturing OTC Opportunity
Capturing OTC Opportunity Global Category Value Share ($ bn) Expanding OTC Business Value Share Capture multi- • Marksans competes in large and billion-dollar OTC growing categories Others 37 opportunity • Increasing store brand penetration in Skin Treatment 15 Strengthening North America Business i
Slide 38: Product Pipeline
Product Pipeline Continued focus on R&D leading to strong product pipeline and successful launches UK US Australia & New Zealand Rest of the World Canada • 18 products approved • 112 new SKUs • 23 SKUs launched in • Built a strong regulatory • 14 products filed during and 30 filings done in launched
Slide 39: Key Product Launches in Last 2 Years
Key Product Launches in Last 2 Years Brand COMPOSITION Therapy Segment Market BENZONATATE CAPSULES BENZONATATE CAPSULES USP, 100 mg & 200 mg Cough and Cold US CETIRIZINE DIHYDROCHLORIDE CETIRIZINE DIHYDROCHLORIDE 1 MG/ML ORAL SOLUTION Anti Allergy UK LOPERAMIDE HYDROCHLORIDE LOPERAMIDE HYDROCHLORIDE
Slide 40: Strong Balance Sheet to Drive Inorganic Growth
Strong Balance Sheet to Drive Inorganic Growth Cash balance of ₹ 990 cr as of 31st March 2026. Cash positive for over 5 years. Low financial risk Consistent operating cash generation ₹ 458 cr in FY26 Driving inorganic growth. Evaluating acquisitions in Europe Disciplined capital allocation region fo
Slide 41: We've Delivered What We Promised
We’ve Delivered What We Promised 1 Total Income guidance of ₹ 3,000 cr Achieved 2 Focus on expanding OTC business – ~5.3x revenue growth since 2017 Achieved 3 EBITDA margins in the 19-20% range Achieved 4 Maintain net cash balance sheet Achieved 5 Disciplined capex allocation Achieved www.marksansph
Slide 42: The Marksans Investment Thesis
The Marksans Investment Thesis Scalable Operating Consistent Execution & 01 Structural Shift to OTC 02 Growth Visibility 03 Leverage 04 Financial Strength • Global OTC market reaching $215 bn — • Multiple drivers: launches, categories, • 26 bn unit capacity; Goa Unit 2 doubling • OTC revenue CAGR 20
Slide 43: Growth Roadmap — FY26 and Beyond
Growth Roadmap — FY26 and Beyond Marksans Growth Algorithm FY27–28 Milestones Strategic Vision FY30 ● India capacity: 16 bn units ● Top global consumer p.a. healthcare company DEEPEN • Increase SKUs per existing retailer ● Expand US and North ● Multi-continent front-end • Expand share in core OTC ca
Slide 44: Sustainability at Marksans
Sustainability at Marksans www.marksanspharma.com Page 43
Slide 45: Driving Sustainable Progress
Driving Sustainable Progress Environment Social Governance Ensure sustainability in our Positively impact our people Bring about an industry operations and projects by and community through utmost transformation by leading ethically positively impacting the natural respect for human rights, and bols
Slide 46: Empowering Communities
Empowering Communities 01 02 03 04 05 Health Care Education Environment Food Distribution Overall wellbeing of women • Organized free health • Contribution towards • Building and upkeep of • Distribution of free and children check-up camps and education of public gardens/parks food items to daily •
Slide 47: Environmental Sustainability Initiatives
Environmental Sustainability Initiatives Improving operational and manufacturing efficiency and attract environmentally conscious value chain partners and focusing on optimum use of natural resources and raw materials Increased use of recycled packaging materials by over 400%. Plan underway for usin
Slide 48: Corporate Governance Standards
Corporate Governance Standards A strong ethical organization with a focus on Has stringent codes of conduct and transparency, accountability, adequate policies in place for observance by disclosure and compliance directors, employees, and workers Robust risk management framework for proactive Has in
Slide 49: Board of Directors - Guided By Visionary Minds
Board of Directors - Guided By Visionary Minds Mark Saldanha Sandra Saldanha Varddhman Jain Dr. Sunny Sharma Founder, Chairman & Promoter, Whole-Time Director Non-Executive Director Managing Director Whole-Time Director • Science Graduate • MA in Arts (Sociology) • M. Pharm (Pharmaceuticals) • MBA,
Slide 50: Board of Directors - Guided By Visionary Minds
Board of Directors - Guided By Visionary Minds Abhinna Sundar Mohanty Digant Mahesh Parikh Shailaja Vardhan Mr. Srinivas Mishra Independent Director Independent Director Independent Director Independent Director • M.Sc., Mathematics • MBA, Finance • Seasoned professional in • B. Sc Hons (Mathematics
Slide 51: Experienced Leadership Team
Experienced Leadership Team Mark Saldanha Varddhman Jain Sathish Kumar Anjani Kumar David Mohammed Jitendra M Sharma Founder, Chairman & Whole-Time Director MD – Marksans Pharma COO – Global Operations MD – Pharmaceuticals Chief Financial Officer Managing Director UK Ltd. and USA Australasia Pty Ltd
Slide 52: Annexure
Annexure www.marksanspharma.com Page 51
Slide 53: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (₹ cr.) Q4FY26 Q4FY25 Q3FY26 YoY QoQ FY26 FY25 YoY Total Income 891.3 723.8 774.6 23.1% 15.1% 3,033.5 2,689.2 12.8% Operating Revenue 856.1 708.5 754.4 20.8% 13.5% 2,950.9 2,622.8 12.5% Gross Profit 465.5 383.2 438.2 21.5% 6.2% 1,673.7 1,479.1 13.2% G
Slide 54: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (₹ cr) FY26 FY25 Particulars (₹ cr) FY26 FY25 EQUITY AND LIABILITIES ASSETS EQUITY NON-CURRENT ASSETS Share capital 45.3 45.3 Property, plant & equipment 925.9 886.4 Reserves and surplus 2,977.8 2,421.6 Capital work-in-progress 14.8 9.0 Non-Controlling interest
Slide 55: Shareholding Pattern — As of March 2026
Shareholding Pattern — As of March 2026 Shareholding — Q4FY26 (Mar 2026) Shareholding Trend – Q4FY26 Category Q4FY26 Promoters (%) 43.9 32.7% 43.9% FII / FPI (%) 16.8 of which OrbiMed (%) 8.6 6.6% 8.2% 8.6% DII (%) 6.6 Public & Others (%) 32.7 Promoters OrbiMed (foreign) Other FII/FPI Source: BSE DI
Slide 56: Thank You
Thank You For more information please contact: Jitendra Sharma (CFO) Corporate Office Marksans Pharma Ltd. 11th Floor Grandeur, Off Veera Desai Road, Tel: +91 22 4001-2000 jitendra@marksanspharma.com Opp Gundecha Symphony, Andheri (W), Mumbai – 400 053, Maharashtra - India © 2025 Marksans Pharma Ltd